First Opinion is a platform on STAT that publishes articles about life sciences, written by experts in biotech, healthcare, and research. Readers can engage in discussions by submitting Letters to the Editor in response to these articles. One article discusses the need for Congress to prioritize funding for rare childhood diseases, highlighting the lack of FDA-approved treatments for many rare conditions. Another article examines the complexities of drug pricing and the role of pharmacy benefit managers in negotiating prices. A third article calls for empathy and investigation into reported vaccine injuries, criticizing the CDC and NIH for failing to examine adverse event data thoroughly.
Source link
Readers respond to a plea for rare disease progress and more
